Medtechs Must Reflect On China Localization Policies As VBP Expands

China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.

China growth

China's volume-based procurement (VBP) scheme is already in its fourth round for medical devices – and 10th round for pharma – and companies affected by these price-cutting schemes should be preparing their growth strategies locally.

That was the advice of Hua Su, life science and healthcare practice leader and partner at Ernest & Young Parthenon,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Asia

More from Geography